Vanda Pharmaceuticals is showcasing Fanapt at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Fanapt's bipolar I expansion (2024) gives it a fresh story at APA, but it will play second fiddle to the Bysanti launch. Over 100,000 patient-years of real-world experience is a safety/familiarity selling point. Psychiatrists who know Fanapt for schizophrenia may not be aware of the bipolar indication.
Ask about: Bipolar I acute manic/mixed uptake since 2024 approval; how they position Fanapt vs. Bysanti within their own portfolio; real-world safety/tolerability profile with 100K+ patient-years.
ePRO+ and VoiceVitals capture real-world outcomes for the new bipolar indication — generating evidence to support awareness and uptake among psychiatrists who know Fanapt only for schizophrenia.
Set up a follow-up with Vanda Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →